|
|
|
|
| LEADER |
02334 am a22002773u 4500 |
| 001 |
70493 |
| 042 |
|
|
|a dc
|
| 100 |
1 |
0 |
|a Goldberg, Michael Solomon
|e author
|
| 100 |
1 |
0 |
|a Massachusetts Institute of Technology. Department of Biology
|e contributor
|
| 100 |
1 |
0 |
|a Koch Institute for Integrative Cancer Research at MIT
|e contributor
|
| 100 |
1 |
0 |
|a Sharp, Phillip A.
|e contributor
|
| 100 |
1 |
0 |
|a Goldberg, Michael Solomon
|e contributor
|
| 100 |
1 |
0 |
|a Sharp, Phillip A.
|e contributor
|
| 700 |
1 |
0 |
|a Sharp, Phillip A.
|e author
|
| 245 |
0 |
0 |
|a Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression
|
| 260 |
|
|
|b Rockefeller University Press, The,
|c 2012-05-03T18:18:05Z.
|
| 856 |
|
|
|z Get fulltext
|u http://hdl.handle.net/1721.1/70493
|
| 520 |
|
|
|a Online supplemental material is available at http://www.jem.org/cgi/content/full/jem.20111487/DC1.
|
| 520 |
|
|
|a The development of cancer-specific therapeutics has been limited because most healthy cells and cancer cells depend on common pathways. Pyruvate kinase (PK) exists in M1 (PKM1) and M2 (PKM2) isoforms. PKM2, whose expression in cancer cells results in aerobic glycolysis and is suggested to bestow a selective growth advantage, is a promising target. Because many oncogenes impart a common alteration in cell metabolism, inhibition of the M2 isoform might be of broad applicability. We show that several small interfering (si) RNAs designed to target mismatches between the M2 and M1 isoforms confer specific knockdown of the former, resulting in decreased viability and increased apoptosis in multiple cancer cell lines but less so in normal fibroblasts or endothelial cells. In vivo delivery of siPKM2 additionally causes substantial tumor regression of established xenografts. Our results suggest that the inherent nucleotide-level specificity of siRNA can be harnessed to develop therapeutics that target isoform-specific exons in genes exhibiting differential splicing patterns in various cell types.
|
| 520 |
|
|
|a MIT-Harvard Center for Cancer Nanotechnology Excellence
|
| 520 |
|
|
|a National Cancer Institute (U.S.) (Grant U54 CA151884)
|
| 520 |
|
|
|a Marie D. and Pierre Casimir-Lambert Fund
|
| 520 |
|
|
|a National Cancer Institute (U.S.) (Cancer Center Support (core) grant P30-CA14051)
|
| 546 |
|
|
|a en_US
|
| 655 |
7 |
|
|a Article
|
| 773 |
|
|
|t Journal of Experimental Medicine
|
